<DOC>
	<DOC>NCT01730040</DOC>
	<brief_summary>This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).</brief_summary>
	<brief_title>Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Patients with screening (visit 1) LDLC greater than or equal to 70 mg/dL with documented CVD, not adequately controlled with a daily dose of atorvastatin. OR 2. Patients with screening (visit 1) LDLC greater than or equal to 100 mg/dL at high risk for CVD who are not adequately controlled with a daily dose of atorvastatin. 1. LDLC greater than 250 mg/dL 2. LDLC less than 70 mg/dL at the screening visit in patients with history of documented CVD 3. LDLC less than 100 mg/dL at the screening visit in patients without history of documented CHD or nonCHD CVD, but with other risk factors 4. TG greater than 400 mg/dL 5. Homozygous FH (clinically or previous genotyping) 6. Currently taking a statin that is not atorvastatin 7. Currently taking Ezetimibe (EZE) 8. Not on a stable dose of allowable lipid modifying treatments (LMT) (The inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>